alfa-2b weekly + 800 mg of ribavirin daily + telaprevir (750 mg/ 8 h) she achieved undetectable HCV-RNA at weeks 4 and 12. Treatment was complicated by severe anaemia, requiring pegylated interferon and ribavirin dose reduction and blood transfusion. HCV-RNA remained ,15 IU/L, and she continued on pegylated interferon + ribavirin treatment. HIV-RNA remained undetectable at treatment weeks 4, 8 and 12.
Darunavir and telaprevir PK data are shown in Table 1 . There were decreases in all darunavir PK parameters when administered with telaprevir for both patients, except for unbound trough concentration in Patient 2. These decreases, ranging from 58% to 97%, were even higher than those previously described in healthy volunteers. 2, 3 However, darunavir/ritonavir doses were different in both cases (800/100 mg once daily in our patients and 600/ 100 mg twice daily in healthy volunteers). 2 We also observed decreases in unbound darunavir concentrations in both patients (except for the aforementioned increase in unbound C trough in Patient 2), although the free fraction decreased less than total drug (ranging from 46% to 93%). There are scarce data on darunavir PK in HIV/HCV-coinfected patients: in a Spanish cohort, darunavir once-daily concentrations (total and unbound) were higher than those observed in our two patients, even before telaprevir co-administration. 5 We could not evaluate the impact of darunavir on telaprevir concentrations, as antiretroviral therapy was maintained. However, telaprevir concentrations in our patients were much higher than previously reported in healthy volunteers or HCV-monoinfected patients. 2, 3, 6 These high telaprevir concentrations in our coinfected patients with advanced fibrosis could partially explain the marked reduction in darunavir levels, although an association between telaprevir exposure and extent of drug interaction with antiretrovirals has not been previously described.
Despite the impact of telaprevir co-administration on darunavir concentrations (total darunavir C trough was below wild-type virus IC 50 in one patient), HIV-RNA remained undetectable during the 12 weeks of telaprevir therapy. Prolonged HIV suppression prior to starting anti-HCV therapy, preserved antiviral potency of the darunavir-based regimen and interferon anti-HIV effect 7 could have played a role in keeping HIV-RNA undetectable.
Having only two patients, we must take into account all the potential confounding factors and the inter-and intra-individual variability, which hamper generalization of our results. However, our results are concordant between both patients. Besides, as PK parameters can be modified with hepatic impairment, it is very important to have data on interaction between telaprevir and darunavir/ ritonavir in HIV/HCV-coinfected patients with hepatic cirrhosis.
In summary, decreases in darunavir total and unbound concentrations were seen in two HIV/HCV-coinfected patients when co-administered with telaprevir. Data from larger trials with once-daily and twice-daily darunavir are necessary in order to find the most appropriate darunavir dose in coinfected patients receiving telaprevir. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 2 Maraviroc and raltegravir appeared well tolerated, with low metabolic toxicity. 3, 4 The aim of this study was to explore the efficacy of a dual simplification regimen including maraviroc and raltegravir in highly experienced patients.
The study included 26 HIV-1-infected highly experienced patients followed at San Raffaele Scientific Institute who were successfully rescued with a complex regimen including maraviroc and raltegravir; their treatment was simplified to dual therapy consisting of maraviroc (300 mg twice daily) and raltegravir (400 mg twice daily) and they were followed prospectively for 24 weeks with monthly visits. Before simplification, patients underwent a co-receptor tropism test on HIV DNA using the geno2pheno algorithm with a false positive rate (FPR) cut-off of 20%, in accordance with European guidelines; at baseline all patients had R5 tropic virus and their antiretroviral regimen was simplified.
In the case of viral rebound (a single value of HIV RNA .50 copies/mL), treatment was immediately re-intensified to the previous full regimen. At viral rebound, resistance tests for viral tropism, reverse transcriptase, protease and integrase were performed. Therapeutic drug monitoring (TDM) was performed using validated methods 5, 6 at simplification (baseline), at week 8, at week 24 and at virological failure.
Results are described as median (IQR) or frequency (%). Intention-to-treat analysis was performed. Changes since baseline were evaluated by the Wilcoxon signed rank test and comparisons between groups were performed using the MannWhitney U-test.
The baseline characteristics of the patients were as follows: 24 (92%) males; 6 (23%) co-infected with hepatitis C virus; 11 (42%) in CDC stage C; age 48 (46 -54) years; duration of HIV infection 20.1 (17.4 -24.1) years; duration of antiretroviral therapy (ART) 16.3 (15.1-19.8) years; CD4+ cell count 654 (507-755) cells/mL; and FPR 50% (43% -69%). All patients had been on optimal viral suppression [10 (38%) with ,1 copy/mL] for 46 (41 -49) months; for 16 and 10 patients, treatment was simplified from regimens including maraviroc, raltegravir and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (88% etravirine) or maraviroc, raltegravir and protease inhibitors (PIs) (80% darunavir/ ritonavir), respectively. By week 24, nine patients (35%) had viral rebound [HIV RNA at virological failure: 2309 (1088 -7719) copies/mL]: five patients (56%) had previously been treated with NNRTIs and four (44%) with PIs. All of them restarted their original therapy: 7/9 (78%) achieved an undetectable viral load within 12 weeks; failed patients changed antiretroviral therapy and currently viruses are undetectable in them.
Regimen, genotypes and FPR at simplification and at failure are reported in Table 1 Figure S1 (available as Supplementary data at JAC Online).
Dual therapies may reduce exposure to drug toxicity and are therefore appealing in patients with long-term treatment experience; we chose the combination of raltegravir and maraviroc because of their efficacy and good tolerability. 7 Nevertheless, this simplification strategy led to an unexpectedly high rate of virological rebound over 24 weeks. In a recently reported study (the ROCnRAL study), 8 patients with lipoatrophy were switched to raltegravir and maraviroc: this trial was prematurely discontinued because of a high rate of virological failure (16% in 48 weeks).
Switching of maraviroc from previous adjusted dosing with PI/ ritonavir and NNRTI to standard dosing with raltegravir led to an expected decrease in maraviroc plasma exposure, especially in patients switching from PI-associated dosing. However, in patients with virological failure this decrease was significantly more marked compared with other subjects, leading to suboptimal exposure in 78% and suggesting a possible additional role of adherence or drug -drug interaction. Data from healthy subjects showed that co-administration of raltegravir and maraviroc led to a decrease in C min of the latter; although considered not generally relevant, the magnitude of the interaction could be more pronounced in some patients. 9 In the ROCnRAL trial, however, the pharmacokinetic substudy did not find evidence of significant maraviroc and raltegravir interactions. 10 The removal of an antiretroviral drug with a high genetic barrier may be a further explanation for the observed results relating to the virological robustness of the regimen.
Despite the small sample size, our findings suggest that the simplification to a dual regimen with maraviroc and raltegravir after successful rescue in patients infected with R5 HIV may be associated with short-term viral rebound.
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